ALDOCLOR-150 (chlorothiazide; methyldopa) by Merck & Co. is clinical pharmacology: the mechanism of the antihypertensive effect of thiazides is unknown. Approved for pregnancy, just, heart failure and 2 more indications. First approved in 1968.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ALDOCLOR-150 is a fixed-dose oral combination of chlorothiazide (a thiazide diuretic) and methyldopa (a centrally-acting antihypertensive) approved in 1968 for hypertension management. Chlorothiazide promotes sodium and chloride excretion in the distal renal tubule, while methyldopa's mechanism remains incompletely understood; together they provide dual-action blood pressure reduction. This product is indicated for hypertension and historically for heart failure, though labeling reflects outdated pregnancy-related indications.
ALDOCLOR-150 is in terminal decline with no active Part D market presence; any remaining commercial team is likely minimal and focused on legacy business retention.
CLINICAL PHARMACOLOGY: The mechanism of the antihypertensive effect of thiazides is unknown. Chlorothiazide does not usually affect normal blood pressure. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are…
Worked on ALDOCLOR-150 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ALDOCLOR-150 offers minimal career growth or visibility; any remaining roles are typically at smaller regional distributors or in legacy brand maintenance functions at larger companies. Merck's portfolio focus has moved substantially toward newer modalities, making ALDOCLOR-150 a marginal, low-stakes assignment unlikely to accelerate career trajectory.